Lorlatinib Clinical Trials
7 recruitingDrug
Phase 23Not Applicable1Phase 11Early Phase 11Phase 31
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Memorial Sloan Kettering Cancer Center56 enrolled6 locationsNCT06007937
Recruiting
Not Applicable
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
ALK+ Non-Small-Cell Lung Carcinoma
Pfizer90 enrolled4 locationsNCT06487078
Recruiting
Early Phase 1
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
GlioblastomaGlioblastoma MultiformeHigh Grade Glioma+6 more
Nationwide Children's Hospital15 enrolled18 locationsNCT06333899
Recruiting
Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
NeuroblastomaGanglioneuroblastoma, NodularGanglioneuroblastoma
Children's Oncology Group750 enrolled162 locationsNCT03126916
Recruiting
Phase 2
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
Centro di Riferimento Oncologico - Aviano45 enrolled9 locationsNCT06378892
Recruiting
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Real World StudyALK-positive Non-small Cell Lung Cancer
Sichuan Cancer Hospital and Research Institute200 enrolled1 locationNCT06361589
Recruiting
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
CancerNeoplasmNeoplasia+1 more
The Netherlands Cancer Institute1,550 enrolled36 locationsNCT02925234